Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Curr Mol Med ; 17(2): 118-132, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28266275

RESUMEN

The Endoplasmic Reticulum (ER) provides a conserved protein quality control system and plays a fundamental role in cell growth and homeostasis. Disturbances in the ER homeostasis may originate especially from hypoxia, glucose deficiency, presence of mutant proteins, that directly impair protein folding capacity and after deposition of unfolded and misfolded proteins within ER lumen trigger ER stress conditions. This subsequently activates the Unfolded Protein Response (UPR) branches, which have a dual pro-adaptive or pro-apoptotic role depending on the severity and time of duration of ER stress conditions. This review is the first to offer a detailed overview on molecular mechanisms of all major ER stress-dependent signaling branches, that are activated through three specific ER transmembrane receptors of impaired protein folding: Protein kinase RNA (PKR)-like ER kinase (PERK), Inositol-requiring enzyme-1 (IRE1) and Activating transcription factor 6 (ATF6). Molecular crosstalk among ER transmembrane receptors-dependent pathways determines a final UPR response, but the recent data reported that especially PERK over-activation has a significant impact on the development and progression of a wide spectrum of disease entities. Based on these findings, small-molecules, highly specific PERK inhibitors may provide effective, groundbreaking treatment strategy against human diseases. However, after foregoing in vitro cellular and in vivo animal models conducted examination, supplementary investigations of PERK inhibitors are required for their further clinical use. Future research may answer the question of how to minimize toxicity and side effects of characterized small-molecule PERK inhibitors, that may be used, as breakthrough drugs, alone or in combination with currently known models of therapy.


Asunto(s)
Estrés del Retículo Endoplásmico/efectos de los fármacos , Terapia Molecular Dirigida , Transducción de Señal/efectos de los fármacos , Factor de Transcripción Activador 6/metabolismo , Animales , Apoptosis/efectos de los fármacos , Biomarcadores , Supervivencia Celular/efectos de los fármacos , Susceptibilidad a Enfermedades , Descubrimiento de Drogas , Endorribonucleasas/metabolismo , Humanos , Diana Mecanicista del Complejo 1 de la Rapamicina , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Respuesta de Proteína Desplegada/efectos de los fármacos , eIF-2 Quinasa/metabolismo
2.
Curr Mol Med ; 16(6): 533-44, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27211800

RESUMEN

Hypoxia is a major hallmark of the tumor microenvironment that is strictly associated with rapid cancer progression and induction of metastasis. Hypoxia inhibits disulfide bond formation and impairs protein folding in the Endoplasmic Reticulum (ER). The stress in the ER induces the activation of Unfolded Protein Response (UPR) pathways via the induction of protein kinase RNA-like endoplasmic reticulum kinase (PERK). As a result, the level of phosphorylated Eukaryotic Initiation Factor 2 alpha (eIF2α) is markedly elevated, resulting in the promotion of a pro-adaptive signaling pathway by the inhibition of global protein synthesis and selective translation of Activating Transcription Factor 4 (ATF4). On the contrary, during conditions of prolonged ER stress, pro-adaptive responses fail and apoptotic cell death ensues. Interestingly, similar to the activity of the mitochondria, the ER may also directly activate the apoptotic pathway through ER stress-mediated leakage of calcium into the cytoplasm that leads to the activation of death effectors. Apoptotic cell death also ensues by ATF4-CHOP- mediated induction of several pro-apoptotic genes and suppression of the synthesis of anti-apoptotic Bcl-2 proteins. Advancing molecular insight into the transition of tumor cells from adaptation to apoptosis under hypoxia-induced ER stress may provide answers on how to overcome the limitations of current anti-tumor therapies. Targeting components of the UPR pathways may provide more effective elimination of tumor cells and as a result, contribute to the development of more promising anti-tumor therapeutic agents.


Asunto(s)
Factor de Transcripción Activador 4/genética , Factor 2 Eucariótico de Iniciación/genética , Regulación Neoplásica de la Expresión Génica , Neoplasias/genética , Factor de Transcripción CHOP/genética , eIF-2 Quinasa/genética , Factor de Transcripción Activador 4/metabolismo , Animales , Apoptosis , Hipoxia de la Célula , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/metabolismo , Transformación Celular Neoplásica/patología , Progresión de la Enfermedad , Retículo Endoplásmico/metabolismo , Estrés del Retículo Endoplásmico/genética , Factor 2 Eucariótico de Iniciación/metabolismo , Humanos , Neoplasias/metabolismo , Neoplasias/patología , Transducción de Señal , Factor de Transcripción CHOP/metabolismo , Respuesta de Proteína Desplegada , eIF-2 Quinasa/metabolismo
3.
Pol J Vet Sci ; 16(2): 381-3, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23971208

RESUMEN

Effectiveness of long-term anti-BVDV vaccination program in reducing prevalence of persistent BVDV infection in cattle herds was evaluated in seven years observational study (2005-2011). Among three seropositive dairy cattle herds (within herd seroprevalence 100%, confirmed by ELISA Herd Check BVDV Ab, IDEXX, Sweden) vaccination program based on inactivated vaccine (cytopathic strain 5960) was commenced in 2007 in two herds and continued till 2010. In the years 2007-2011 all calves aged 2-12 weeks in all three herds were tested yearly with RT-PCR in order to detect persistently infected individuals. For the entire study period true prevalence of BVDV persistent infection was significantly lower in vaccinated than in non-vaccinated herd. This may imply the role of long-term vaccination program in reducing prevalence of persistent BVDV infection in cattle herds.


Asunto(s)
Diarrea Mucosa Bovina Viral/prevención & control , Virus de la Diarrea Viral Bovina , Vacunas Virales/inmunología , Animales , Anticuerpos Antivirales/sangre , Diarrea Mucosa Bovina Viral/sangre , Diarrea Mucosa Bovina Viral/epidemiología , Bovinos , Industria Lechera , Ensayo de Inmunoadsorción Enzimática/veterinaria , Femenino , Prevalencia , Sensibilidad y Especificidad , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA